Results 121 to 130 of about 17,271 (194)

Global management of drug-drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist. [PDF]

open access: yesOncologist
Valsecchi AA   +16 more
europepmc   +1 more source

Identifying serum biomarkers for predicting the resistance of enzalutamide or abiraterone in prostate cancer patients

open access: yes
[[abstract]]Abiraterone acetate and enzalutamide are useand can increase the life span of CRPC patients for a few months. However, approximately 40% of patients do not respond to treatment with enzalutamide or abiraterone and the majority of patients who
Chuu, CP;Lin, TP;Huo, C
core  

Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. [PDF]

open access: yesBr J Cancer
Elsesy ME   +17 more
europepmc   +1 more source

Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer.

open access: yesJAMA Netw Open
Gebrael G   +16 more
europepmc   +1 more source

3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer. [PDF]

open access: yesMol Cancer Res
Bitaraf M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy